

Celestia Biotech presents clinical results from the Phase 1 study of its novel gene transcription factor inhibitor CB-103 in advanced solid tumors at the 2021 ASCO Annual Meeting.

Basel, Switzerland – 1st of June 2021– Celestia Biotech, specialized in targeting Transcription Factors (TFs) involved in human diseases will present updated clinical data of its ongoing Phase 1 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021 underscoring the ambition to become a leader in the field of TFs.

Dr. Florian Vogl, CMO of Celestia Biotech said: “Our clinical data at ASCO this year validate our transformative scientific approach and open the path for CB-103 to become a new treatment option for patients with NOTCH-driven cancers and non-oncology conditions such as autoimmune and inflammatory diseases.”

Dr. Michael Bauer, CEO of Celestia stated: “Cellestia is shifting the boundaries of biomedical research: the outstanding clinical data on CB-103 confirm Cellestia’s ability to develop novel therapies targeting Transcription Factors that historically have been considered difficult or impossible to target. We have shown we can do it and we will further expand our pipeline to address currently unmet medical needs.”

Presentation details:

Title: Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers

Abstract Number: 3020

Session: Poster Discussion Session, Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Presenting Author: Elena López-Miranda, MD, Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain

Date / Time: (Virtual) Friday, June 4th, poster and recording available on demand at ASCO.org from 9:00 AM EST

A copy of the poster can be accessed on www.cellestia.com after the presentation concludes, and the recorded oral presentation will be hosted on the online ASCO Meeting Library.

About Celestia's clinical Phase 1 trial

CB103-C-101 is a Phase 1/2a multicenter, open-label, dose-escalation study with expansion arms of CB-103 in adult patients with locally advanced or metastatic solid tumors and hematological malignancies characterized by alterations of the Notch signaling pathway. The study is open for enrollment at sites in Europe and Switzerland, the US, and Asia (China, Korea).

About Transcription Factors (TF)

Transcription refers to the first step of gene expression where an RNA is created from a DNA template. Transcription factors (TF) are DNA-binding proteins that play a key role in gene transcription. Through their ability to initiate or repress site-specific transcription, each cell in our bodies can differentiate into a different cell type despite containing the same exact genetic code. Transcription factors also make genetic fine-tuning possible. Modulating the activity and the amount of transcription factor can increase or decrease the rates of the chosen gene's transcription. Ultimately, transcription factors can be thought of as the "gatekeepers" that determine if a gene is expressed or not.

About Celestia Biotech

Celestia is a biopharmaceutical company specialised in research and development of first-in-class drugs targeting gene transcription factors enabling the treatment of multi-drug resistant cancers as well as a wide range of non-cancer indications. This innovative approach has successfully led to a pipeline of proprietary drug candidates. Celestia's lead molecule CB-103 is a first-in-class inhibitor of the TF complex. Clinical phase 1 data showed that CB 103 is the first drug that can control oncogenic pathway activation effectively and safely, in absence of any severe toxicities. Celestia holds a worldwide exclusive license on the intellectual property rights for CB-103 and related series of analogues, for development and commercialization. The company pursues an integrated approach combining drug and personalized medicine development for patient selection.

Media Inquiries

Dr. Michael Bauer, CEO
+41 61 633 29 80
michael.bauer@celestia.com

Gaudenz von Capeller, CFO
+41 79 798 64 43
gaudenz.voncapeller@celestia.com